|
|
Exchange: |
New York Stock Exchange |
Security
Type: |
Common |
Shares
Out: |
2,630,000,000 |
Market
Cap: |
385.08(B) |
Last
Volume: |
5,016,259 |
Avg
Vol: |
8,298,662 |
52
Week Range: |
$144.38 - $174.48 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
DOW JONES COMPOSITE |
|
DOW JONES INDUSTRIAL AVERAGE |
|
NYSE COMPOSITE |
|
S&P 100 |
|
S&P 500 |
|
MAJOR MARKET |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 21 |
Guru Rank Value : 20.3 |
Guru Occurances : 6 |
|
|
|
|
|
|
|
Company Profile Johnson & Johnson is a holding company. Through its subsidiaries, Co. is engaged in the research and development, manufacture and sale of products in the health care field. Co. has three business segments: Consumer Health, which includes products focused on personal healthcare used in the skin health/beauty, over-the-counter medicines, baby care, oral care, women's health and wound care markets; Pharmaceutical, which is focused on six therapeutic areas: Immunology, Infectious Diseases, Neuroscience, Oncology, Cardiovascular and Metabolism and Pulmonary Hypertension; and Medical Devices, which includes products used in the Interventional Solutions, Orthopaedics, Surgery, and Vision fields.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
8,891 |
68,288 |
115,451 |
513,708 |
Total Sell Value |
$1,441,765 |
$10,723,734 |
$18,652,688 |
$87,322,011 |
Total People Sold |
1 |
2 |
5 |
10 |
Total Sell Transactions |
1 |
2 |
5 |
23 |
End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Taubert Jennifer L |
EVP, WW Chair, Pharmaceuticals |
|
2024-02-09 |
4 |
S |
$156.27 |
$9,281,969 |
D/D |
(59,397) |
141,416 |
|
7% |
|
Taubert Jennifer L |
EVP, WW Chair, Pharmaceuticals |
|
2024-02-09 |
4 |
OE |
$90.44 |
$5,371,865 |
D/D |
59,397 |
200,813 |
|
- |
|
Wolk Joseph J |
Exec VP, CFO |
|
2024-02-08 |
4 |
D |
$156.33 |
$163,678 |
D/D |
(1,047) |
52,864 |
|
- |
|
Wolk Joseph J |
Exec VP, CFO |
|
2024-02-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,686 |
53,911 |
|
- |
|
Duato Joaquin |
CEO and Chairman of the Board |
|
2024-02-08 |
4 |
D |
$156.33 |
$354,713 |
D/D |
(2,269) |
308,314 |
|
- |
|
Duato Joaquin |
CEO and Chairman of the Board |
|
2024-02-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,225 |
310,583 |
|
- |
|
Swanson James D. |
See Remarks |
|
2024-02-08 |
4 |
D |
$156.33 |
$86,607 |
D/D |
(554) |
10,557 |
|
- |
|
Swanson James D. |
See Remarks |
|
2024-02-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,868 |
11,111 |
|
- |
|
Forminard Elizabeth |
Executive VP, General Counsel |
|
2024-02-08 |
4 |
D |
$156.33 |
$56,748 |
D/D |
(363) |
6,100 |
|
- |
|
Forminard Elizabeth |
Executive VP, General Counsel |
|
2024-02-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
979 |
6,463 |
|
- |
|
Wengel Kathryn E |
EVP, Chief TO and Risk Officer |
|
2024-02-08 |
4 |
D |
$156.33 |
$157,737 |
D/D |
(1,009) |
66,896 |
|
- |
|
Wengel Kathryn E |
EVP, Chief TO and Risk Officer |
|
2024-02-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,971 |
67,905 |
|
- |
|
Fasolo Peter |
Exec VP, Chief HR Officer |
|
2024-02-08 |
4 |
D |
$156.33 |
$122,094 |
D/D |
(781) |
103,684 |
|
- |
|
Fasolo Peter |
Exec VP, Chief HR Officer |
|
2024-02-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,135 |
104,465 |
|
- |
|
Broadhurst Vanessa |
EVP, Global Corp Affairs |
|
2024-02-08 |
4 |
D |
$156.33 |
$109,900 |
D/D |
(703) |
20,380 |
|
- |
|
Broadhurst Vanessa |
EVP, Global Corp Affairs |
|
2024-02-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,880 |
21,083 |
|
- |
|
Hait William |
See Remarks |
|
2024-02-08 |
4 |
D |
$156.33 |
$173,995 |
D/D |
(1,113) |
33,384 |
|
- |
|
Hait William |
See Remarks |
|
2024-02-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,059 |
34,497 |
|
- |
|
Schmid Timothy |
EVP, WW Chair, MedTech |
|
2024-02-08 |
4 |
D |
$156.33 |
$156,486 |
D/D |
(1,001) |
9,942 |
|
- |
|
Schmid Timothy |
EVP, WW Chair, MedTech |
|
2024-02-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,964 |
10,943 |
|
- |
|
Decker Robert J |
VP Corporate Controller |
|
2024-02-08 |
4 |
D |
$156.33 |
$33,611 |
D/D |
(215) |
17,357 |
|
- |
|
Decker Robert J |
VP Corporate Controller |
|
2024-02-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
655 |
17,572 |
|
- |
|
Taubert Jennifer L |
EVP, WW Chair, Pharmaceuticals |
|
2024-02-08 |
4 |
D |
$156.33 |
$299,059 |
D/D |
(1,913) |
141,416 |
|
- |
|
Taubert Jennifer L |
EVP, WW Chair, Pharmaceuticals |
|
2024-02-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,739 |
143,329 |
|
- |
|
Schmid Timothy |
EVP, WW Chair, MedTechOfficer |
|
2023-10-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
8,979 |
|
6% |
|
606 Records found
|
|
Page 3 of 25 |
|
|